Here, we detected activating PIK3CA mutations, AKT1 mutations, and inactivating PTEN alterations in 76 (54%) of an intention-to-treat population of postmenopausal women with ER-positive, HER2-negative advanced breast cancer who had previously been treated with an aromatase inhibitor. The gene discussed is AKT1; the disease is breast cancer.